rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2021-625-630rsp-3085Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSСочетание ревматоидного артрита и саркоидоза, дебютировавшего на фоне терапии ритуксимабом: клинический случай и обзор литературыCombination of rheumatoid arthritis and sarcoidosis, which had occurred during rituximab therapy, complicated secondary immunodeficiency and intolerance to the main basic drugs: Case repost and literature reviewhttps://orcid.org/0000-0001-7247-545XГоловинаО. А.GolovinaO. A.

Головина Оксана Андреевна

115522, Российская Федерация, Москва, Каширское шоссе, 34а

Oksana Golovina

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-3065-4235ДемидоваН. В.DemidovaN. V.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-9292-6649АлексееваА. В.AlekseevaA. V.

115522, Российская Федерация, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202131102021595625630Copyright © Головина О.А., Демидова Н.В., Алексеева А.В., 20212021Головина О.А., Демидова Н.В., Алексеева А.В.Golovina O.A., Demidova N.V., Alekseeva A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3085

Сочетание ревматоидного артрита и саркоидоза, дебютировавшего на фоне терапии ритуксимабом: клинический случай и обзор литературыСаркоидоз – редкое мультисистемное заболевание, которое может сопутствовать другим аутоиммунным болезням в 17,6% случаев. Несмотря на то, что в патогенезе и ревматоидного артрита, и саркоидоза ключевую роль играет дефект Т-клеточного звена иммунитета, их сочетание встречается крайне редко. Выбор терапии у пациентов с коморбидной патологией всегда представляет определенные сложности. В данной статье рассмотрен сложный случай подбора терапии для пациентки с сочетанием ревматоидного артрита и саркоидоза, который дебютировал на фоне терапии ритуксимабом. Помимо сочетания двух аутоиммунных заболеваний, выбор терапии для данной пациентки был затруднен в связи с наличием вторичного иммунодефицита и непереносимостью основных базисных противовоспалительных препаратов.

Sarcoidosis is a rare multisystem disease which may accompany various autoimmune diseases in 17,6% cases. Despite of the fact that T-cell immunity impairments play a key role in these two conditions, their combination is extremely rare. It is difficult to choose therapy for patients with coexisted diseases, and it is even harder in case of comorbid pathology. In this article we considered a complicated case of treatment patient with a coexistence of rheumatoid arthritis and sarcoidosis, which had occurred during rituximab therapy. In addition to the combination of two autoimmune diseases, the selection of therapy for this patient was complicated by secondary immunodeficiency and intolerance to the main basic drugs.

саркоидозревматоидный артритвторичный иммунодефицитФНО-αsarcoidosisrheumatoid arthritissecondary immunodeficiencyTNF-αReferencesBrito-Zerón P, Acar-Denizli N, Sisó-Almirall A, Bosch X, Hernández F, Vilanova S, et al. The burden of comorbidity and complexity in sarcoidosis: Impact of associated chronic diseases. Lung. 2018;196:239-248. doi: 10.1007/s00408-017-0076-4Brito-Zerón P, Acar-Denizli N, Sisó-Almirall A, Bosch X, Hernández F, Vilanova S, et al. The burden of comorbidity and complexity in sarcoidosis: Impact of associated chronic diseases. Lung. 2018;196:239-248. doi: 10.1007/s00408-017-0076-4Wu CH, Chung PI, Wu CY, Chen YT, Chiu YW, Chang YT, et al. Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case-control study in Taiwan. J Dermatol. 2017;44(4):423-430. doi: 10.1111/1346-8138.13654Wu CH, Chung PI, Wu CY, Chen YT, Chiu YW, Chang YT, et al. Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case-control study in Taiwan. J Dermatol. 2017;44(4):423-430. doi: 10.1111/1346-8138.13654Gumpel J, Johns C, Shulman L. The joint disease of sarcoidosis. Ann Rheum Dis. 1967;26:194-205. doi: 10.1136/ard.26.3.194Gumpel J, Johns C, Shulman L. The joint disease of sarcoidosis. Ann Rheum Dis. 1967;26:194-205. doi: 10.1136/ard.26.3.194Pettersson T. Rheumatic features of sarcoidosis. Curr Opin Rheumatol. 1998;10:73-78. doi: 10.1097/00002281-199801000-00011Pettersson T. Rheumatic features of sarcoidosis. Curr Opin Rheumatol. 1998;10:73-78. doi: 10.1097/00002281-199801000-00011Toussirot E, Aubin F. Paradoxical reactions under TNF-a blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview. RMD Open. 2016;2(2):e000239. doi: 10.1136/rmdopen-2015-000239Toussirot E, Aubin F. Paradoxical reactions under TNF-a blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview. RMD Open. 2016;2(2):e000239. doi: 10.1136/rmdopen-2015-000239Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26(11):1969-1971. doi: 10.1007/s10067-007-0594-1Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26(11):1969-1971. doi: 10.1007/s10067-007-0594-1Menard O, Petit N, Gillet P, Gaucher A, Martinet Y. Association of histologically proven rheumatoid arthritis with pulmonary sarcoidosis. Eur Respir J. 1995;8(3):472-473. doi: 10.1183/09031936.95.08030472Menard O, Petit N, Gillet P, Gaucher A, Martinet Y. Association of histologically proven rheumatoid arthritis with pulmonary sarcoidosis. Eur Respir J. 1995;8(3):472-473. doi: 10.1183/09031936.95.08030472Kobak Ş, Karaarslan AA, Yilmaz H, Sever F. Co-occurrence of rheumatoid arthritis and sarcoidosis. BMJ. 2015:bcr2014208803. doi: 10.1136/bcr-2014-208803Kobak Ş, Karaarslan AA, Yilmaz H, Sever F. Co-occurrence of rheumatoid arthritis and sarcoidosis. BMJ. 2015:bcr2014208803. doi: 10.1136/bcr-2014-208803Vihlborg P, Bryngelsson I-L, Andersson L, Graff P. Risk of sarcoidosis and seropositive rheumatoid arthritis from occupational silica exposure in Swedish iron foundries: A retrospective cohort study. BMJю 2017;7:e016839 doi: 10.1136/bmjopen-2017-016839Vihlborg P, Bryngelsson I-L, Andersson L, Graff P. Risk of sarcoidosis and seropositive rheumatoid arthritis from occupational silica exposure in Swedish iron foundries: A retrospective cohort study. BMJю 2017;7:e016839 doi: 10.1136/bmjopen-2017-016839Calvert GM, Rice FL, Boiano JM, Sheehy JW, Sanderson WT. Occupational silica exposure and risk of various diseases: An analysis using death certificates from 27 states of the United States. Occup Environ Med. 2003;60(2):122-129. doi: 10.1136/oem.60.2.122Calvert GM, Rice FL, Boiano JM, Sheehy JW, Sanderson WT. Occupational silica exposure and risk of various diseases: An analysis using death certificates from 27 states of the United States. Occup Environ Med. 2003;60(2):122-129. doi: 10.1136/oem.60.2.122Iannuzzi MC, Fontana JR. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305:391-399. doi: 10.1378/chest.95.3.604Iannuzzi MC, Fontana JR. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305:391-399. doi: 10.1378/chest.95.3.604Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG, Drijfhout JW, et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum. 2010;62(1):117-125. doi: 10.1002/art.25059Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG, Drijfhout JW, et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum. 2010;62(1):117-125. doi: 10.1002/art.25059Kucera MRF. A possible association of rheumatoid arthritis and sarcoidosis. Chest. 1989;95:604-606.Kucera MRF. A possible association of rheumatoid arthritis and sarcoidosis. Chest. 1989;95:604-606.Chen ES, Moller DR. Etiology of sarcoidosis. Clinics Chest Med. 2008;29:365-377. doi: 10.1016/j.ccm.2008.03.011Chen ES, Moller DR. Etiology of sarcoidosis. Clinics Chest Med. 2008;29:365-377. doi: 10.1016/j.ccm.2008.03.011Wahlström J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanović S, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. 2007;117(11):3576-3582. doi: 10.1172/JCI32401Wahlström J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanović S, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. 2007;117(11):3576-3582. doi: 10.1172/JCI32401Grunewald J, Kaiser Y, Ostadkarampour M, Rivera NV, Vezzi F, Lötstedt B, et al. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. 2016;47(3):898-909. doi: 10.1183/13993003.01209-2015Grunewald J, Kaiser Y, Ostadkarampour M, Rivera NV, Vezzi F, Lötstedt B, et al. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. 2016;47(3):898-909. doi: 10.1183/13993003.01209-2015Eberhardt C, Thillai M, Parker R, Siddiqui N, Potiphar L, Goldin R, et al. Proteomic analysis of Kveim reagent identifies targets of cellular immunity in sarcoidosis. PLoS One. 2017;12(1):e0170285. doi: 10.1371/journal.pone.0170285Eberhardt C, Thillai M, Parker R, Siddiqui N, Potiphar L, Goldin R, et al. Proteomic analysis of Kveim reagent identifies targets of cellular immunity in sarcoidosis. PLoS One. 2017;12(1):e0170285. doi: 10.1371/journal.pone.0170285Saussine A, Tazi A, Feuillet S, Rybojad M, Juillard C, Bergeron A, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One. 2012;7(8):e43588. doi: 10.1371/journal.pone.0043588Saussine A, Tazi A, Feuillet S, Rybojad M, Juillard C, Bergeron A, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One. 2012;7(8):e43588. doi: 10.1371/journal.pone.0043588Лазарева НМ, Кудрявцев ИВ, Баранова ОП, Серебрякова МК, Бажанов АА, Сесь ТП, и др. Анализ субпопуляций В-лимфоцитов в периферической крови больных саркоидозом при разной степени активности заболевания. Медицинская иммунология. 2019;21(6):1081-1098.Lazareva NM, Kudryavtsev IV, Baranova OP, Serebriakova MK, Bazhanov AA, Ses’ TP, et al. Peripheral blood B cell subsets from patients with various activity of chronic sarcoidosis. Medical Immunology (Russia). 2019;21(6):1081-1098 (In Russ.)]. doi: 10.15789/1563-0625-2019-6-1081-1098Spilberg I, Siltzbach L, McEwen C. The arthritis of sarcoidosis. Arthritis Rheum. 1969;12:126-137. doi: 10.1002/art.1780120209Spilberg I, Siltzbach L, McEwen C. The arthritis of sarcoidosis. Arthritis Rheum. 1969;12:126-137. doi: 10.1002/art.1780120209Kobak S, Sever F, Sivrikoz ON, Orman M. Sarcoidois: Is it only a mimicker of primary rheumatic disease? A single center experience. Ther Adv Musculoskelet Dis. 2014;6(1):3-7. doi: 10.1177/1759720X13511197Kobak S, Sever F, Sivrikoz ON, Orman M. Sarcoidois: Is it only a mimicker of primary rheumatic disease? A single center experience. Ther Adv Musculoskelet Dis. 2014;6(1):3-7. doi: 10.1177/1759720X13511197Visser H, Vos K, Zanelli E, Verduyn W, Schreuder GM, Speyer I, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis. 2002;61(6):499-504. doi: 10.1136/ard.61.6.499Visser H, Vos K, Zanelli E, Verduyn W, Schreuder GM, Speyer I, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis. 2002;61(6):499-504. doi: 10.1136/ard.61.6.499Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract Res Clin Rheumatol. 2003;17:97-87. doi: 10.1016/j.berh.2003.09.005Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract Res Clin Rheumatol. 2003;17:97-87. doi: 10.1016/j.berh.2003.09.005Pitt P, Hamilton EB, Innes EH, Morley KD, Monk BE, Hughes GR. Sarcoid dactylitis. Ann Rheum Dis. 1983;42(6):634-639. doi: 10.1136/ard.42.6.634Pitt P, Hamilton EB, Innes EH, Morley KD, Monk BE, Hughes GR. Sarcoid dactylitis. Ann Rheum Dis. 1983;42(6):634-639. doi: 10.1136/ard.42.6.634Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053-2059. doi: 10.1016/j.rmed.2006.02.017Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053-2059. doi: 10.1016/j.rmed.2006.02.017Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3):310.Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3):310.Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, Pérard L, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288-294. doi: 10.1016/j.semarthrit.2017.03.005Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, Pérard L, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288-294. doi: 10.1016/j.semarthrit.2017.03.005Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, et al.; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189-1196. doi: 10.1183/09031936.00051907Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, et al.; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189-1196. doi: 10.1183/09031936.00051907Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175-185. doi: 10.1183/09031936.00227014Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175-185. doi: 10.1183/09031936.00227014Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al.; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795-802. doi: 10.1164/rccm.200603-402OCBaughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al.; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795-802. doi: 10.1164/rccm.200603-402OCRossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller WJr, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201-208.Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller WJr, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201-208.Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765-773. doi: 10.1016/j.jaad.2012.10.056Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765-773. doi: 10.1016/j.jaad.2012.10.056Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713-720. doi: 10.1007/s00417-011-1844-0Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713-720. doi: 10.1007/s00417-011-1844-0Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46-54.Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46-54.Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: A prospective observational study using FDGPET. Clin Respir J. 2012;6(4):238-247. doi: 10.1111/j.1752-699X.2011.00276.xMilman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: A prospective observational study using FDGPET. Clin Respir J. 2012;6(4):238-247. doi: 10.1111/j.1752-699X.2011.00276.xMinnis PA, Poland M, Keane MP, Donnelly SC. Adalimumab for refractory pulmonary sarcoidosis. Ir J Med Sci. 2016;185(4):969-971. doi: 10.1007/s11845-015-1363-9Minnis PA, Poland M, Keane MP, Donnelly SC. Adalimumab for refractory pulmonary sarcoidosis. Ir J Med Sci. 2016;185(4):969-971. doi: 10.1007/s11845-015-1363-9Crommelin HA, van der Burg LM, Vorselaars AD, Drent M, van Moorsel CH, Rijkers GT, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72-77. doi: 10.1016/j.rmed.2016.04.011Crommelin HA, van der Burg LM, Vorselaars AD, Drent M, van Moorsel CH, Rijkers GT, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72-77. doi: 10.1016/j.rmed.2016.04.011Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296-1307. doi: 10.1183/09031936.00000914Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296-1307. doi: 10.1183/09031936.00000914Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177-185. doi: 10.1378/chest.124.1.177Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177-185. doi: 10.1378/chest.124.1.177Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: Results of a double-blind randomized trial. Chest. 2005;128(2):1062-1047. doi: 10.1378/chest.128.2.1062Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: Results of a double-blind randomized trial. Chest. 2005;128(2):1062-1047. doi: 10.1378/chest.128.2.1062Barba T, Marquet A, Bouvry D, Cohen-Aubart F, Ruivard M, Debarbieux S, et al. Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis: Experience from the STAT registry. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(4):343-351. doi: 10.36141/svdld.v34i4.5817Barba T, Marquet A, Bouvry D, Cohen-Aubart F, Ruivard M, Debarbieux S, et al. Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis: Experience from the STAT registry. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(4):343-351. doi: 10.36141/svdld.v34i4.5817Marquet A, Chapelon-Abric C, Maucort-Boulch D, Cohen-Aubart F, Pérard L, Bouillet L, et al.; Groupe Sarcoïdose Francophone. Efficacy and safety of TNF antagonists in ocular sarcoidosis: Data from the French registry STAT. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):74-80. doi: 10.36141/svdld.v34i1.5368Marquet A, Chapelon-Abric C, Maucort-Boulch D, Cohen-Aubart F, Pérard L, Bouillet L, et al.; Groupe Sarcoïdose Francophone. Efficacy and safety of TNF antagonists in ocular sarcoidosis: Data from the French registry STAT. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):74-80. doi: 10.36141/svdld.v34i1.5368Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91-107.Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91-107.Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JG, Perkins D, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525-1528. doi: 10.1183/09031936.00224513Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JG, Perkins D, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525-1528. doi: 10.1183/09031936.00224513Beccastrini E, Vannozzi L, Bacherini D, Squatrito D, Emmi L. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm. 2013;21(3):244-246. doi: 10.3109/09273948.201 2.762982Beccastrini E, Vannozzi L, Bacherini D, Squatrito D, Emmi L. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm. 2013;21(3):244-246. doi: 10.3109/09273948.201 2.762982Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: A single centre experience. Clin Mol Allergy. 2015;13(1):19. doi: 10.1186/s12948-015-0025-9Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: A single centre experience. Clin Mol Allergy. 2015;13(1):19. doi: 10.1186/s12948-015-0025-9Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al.; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64(6):913-920. doi: 10.1136/ard.2004.029694Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al.; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64(6):913-920. doi: 10.1136/ard.2004.029694Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732. doi: 10.1177/1756286418805732Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732. doi: 10.1177/1756286418805732Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568-570. doi: 10.1212/WNL.0b013e3181ec7ff9Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568-570. doi: 10.1212/WNL.0b013e3181ec7ff9Sawaya R, Radwan W. Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci. 2013;20(8):1156-1158. doi: 10.1016/j.jocn.2012.09.030Sawaya R, Radwan W. Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci. 2013;20(8):1156-1158. doi: 10.1016/j.jocn.2012.09.030Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Сlin Ophthalmol. 2012;6:1613-1618. doi: 10.2147/OPTH.S35521Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Сlin Ophthalmol. 2012;6:1613-1618. doi: 10.2147/OPTH.S35521Насонов ЕЛ (ред.). Генно-инженерные биологические препараты в лечении ревматоидрого артрита. М.:ИМА-ПРЕСС;2013:552. [Nasonov EL (ed.). Biological drugs in the treatment of rheumatoid arthritis. Moscow:IMA-PRESS;2013:552 (In Russ.)].Насонов ЕЛ (ред.). Генно-инженерные биологические препараты в лечении ревматоидрого артрита. М.:ИМА-ПРЕСС;2013:552. [Nasonov EL (ed.). Biological drugs in the treatment of rheumatoid arthritis. Moscow:IMA-PRESS;2013:552 (In Russ.)].

The authors declare that there are no conflicts of interest present.